Audio Version: Press Play to Listen
Edinburgh, Scotland (April 25, 2024) - Blackford, the pioneering strategic AI platform and solutions provider, and MedCognetics, the ‘Unbiased’ Medical AI Imaging algorithm experts, today announced a commercial partnership to bring CogNet AI-MT Mammography Algorithm System, to healthcare professionals via the Blackford Platform.
Blackford provides healthcare professionals access to an extensive portfolio of more than 120 AI solutions designed to drive clinical accuracy and efficiency and improve patient outcomes. By integrating MedCognetics’ advanced technology into the Blackford Platform, Blackford can offer healthcare providers more powerful tools to support study prioritization.
"MedCognetics' dedication to enhancing mammography cancer screening aligns perfectly with our goal of utilizing AI to enhance patient well-being and public health," says Ben Panter, Founder and CEO of Blackford. "We are excited to incorporate their innovative applications into the extensive portfolio of AI solutions available to healthcare providers via the Blackford platform."
CogNet AI-MT provides an unbiased advanced imaging algorithm that leverages AI and Machine Learning (ML) to detect the earliest manifestations of cancer in all ethnicities. The digital health software platform can be deployed via various methods – providing customers with one of the most accessible medical AI algorithms on the market.
“A gap exists in the market today as AI solutions are trained primarily using limited homogeneous race or ethnicity data, introducing bias issues for many patients. MedCognetics is committed to levering our technology to help improve outcomes across a diverse group of patients.” said Debasish “Ron” Nag, Chief Executive Officer, MedCognetics, Inc. “In addition to ensuring technology serves all patient groups, our software’s high accuracy enables reduced time for review by radiologists, another key component to improved outcomes. We at MedCognetics are excited of our partnership with Blackford and look forward to the superior clinical outcomes we can deliver together worldwide.”